Cabaletta Bio Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (3)

Latest Posts

About This Stock More About This Stock
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
Article By: ChinaBio® Today
Saturday, October 15, 2022 5:40 PM EDT
Deals, financings, trials and approvals on the China biotech/pharma market.
In this article: RHHBY, BGNE, CABA
Read

Latest Tweets for $CABA

No tweets yet!

PARTNER HEADLINES